Back to Search Start Over

Therapeutic strategies to address monkeypox.

Authors :
McCarthy, Matthew W.
Source :
Expert Review of Anti-infective Therapy; Oct2022, Vol. 20 Issue 10, p1249-1252, 4p
Publication Year :
2022

Abstract

Monkeypox is a viral zoonosis, with symptoms similar to those seen in smallpox patients, although the clinical presentation may be less severe. Until recently, human monkeypox infection was rare, and primarily occurred in Central and West Africa. An international outbreak began in May 2022, and monkeypox has now been detected on every continent except Antarctica. The first recognized case from the current outbreak was confirmed in the United Kingdom on 6 May 2022, in an adult with travel links to Nigeria, but it has been suggested that cases had been spreading in Europe for months. On 23 July 2022 the Director-General of the World Health Organization declared the monkeypox outbreak a public health emergency of international concern. There are no treatments specifically for monkeypox virus infections. However, monkeypox and smallpox viruses are genetically similar, and therapeutics developed to combat smallpox may be used to treat monkeypox. This manuscripts reviews what is known about these potential treatments, including tecovirimat and brincidofovir, based on a literature search of PubMed through 9 August 2022, and explores how these therapeutics may be used in the future to address the expanding monkeypox pandemic. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14787210
Volume :
20
Issue :
10
Database :
Complementary Index
Journal :
Expert Review of Anti-infective Therapy
Publication Type :
Academic Journal
Accession number :
159448085
Full Text :
https://doi.org/10.1080/14787210.2022.2113058